Diagnostic Accuracy of the Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism
Overview
Authors
Affiliations
Context: The aldosterone-to-active renin ratio (AARR) is the recommended screening test for primary aldosteronism (PA), but prospective study data on its sensitivity and specificity are sparse.
Objective: To investigate the diagnostic accuracy of the AARR for detecting PA.
Design: Prospective diagnostic accuracy study.
Setting: This study was conducted from February 2009 to August 2015 at the outpatient clinic of the Department of Endocrinology and Diabetology of the Medical University of Graz, Austria.
Participants: Four hundred patients with arterial hypertension who were referred to a tertiary care center for screening for endocrine hypertension.
Intervention: Participants had a determination of the AARR (index test) and a second AARR determination followed by a saline infusion test (SIT) after 2 to 6 weeks. PA was diagnosed in individuals with any AARR ≥3.7 ng/dL/µU/mL [including a plasma aldosterone concentration (PAC) of ≥9 ng/dL] who had a PAC ≥10 ng/dL after the SIT. We did not substantially alter antihypertensive drug intake.
Main Outcome Measures: Primary outcome was the receiver-operating characteristic (ROC) curve of the AARR in diagnosing PA.
Results: A total of 382 participants were eligible for analyses; PA was diagnosed in 18 (4.7%) patients. The area under the ROC curve of the AARR in detecting PA was 0.973 (95% CI, 0.956 to 0.990). Sensitivity and specificity for a positive AARR in diagnosing PA were 100% (95% CI, 81.5% to 100.0%) and 89.6% (95% CI, 86.0% to 92.5%), respectively.
Conclusions: The AARR has good diagnostic accuracy for detecting PA.
Kao T, Chen J, Liu J, Tseng W, Hsieh C, Wu V Ther Adv Endocrinol Metab. 2024; 15:20420188241303429.
PMID: 39669529 PMC: 11635879. DOI: 10.1177/20420188241303429.
Development of a diagnostic model for pre-washout screening of primary aldosteronism.
Wang Q, Dong H, Li H, Zheng Z, Liu Y, Hua Y J Endocrinol Invest. 2024; 47(10):2539-2550.
PMID: 38536656 PMC: 11393003. DOI: 10.1007/s40618-024-02337-y.
Liu X, Hao S, Bian J, Lou Y, Zhang H, Wu H J Clin Endocrinol Metab. 2024; 109(12):e2302-e2308.
PMID: 38381080 PMC: 11570383. DOI: 10.1210/clinem/dgae094.
The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.
Jedrusik P, Symonides B, Lewandowski J, Gaciong Z Front Pharmacol. 2021; 12:684111.
PMID: 34054559 PMC: 8155700. DOI: 10.3389/fphar.2021.684111.